down arrow

Laboratory Corp. of America Holdings

  • Market Cap: Mid Cap
  • Industry: Miscellaneous
  • ISIN: US50540R4092
USD
261.48
-4.28 (-1.61%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

259.42265.50

52 Week

209.38293.50
Valuation
Technical
Day's Volume

CASH

196.96 k

Shareholding (Mar 2025)

FII

20.08%

Held by 341 FIIs

DII

37.48%

Held by 54 DIIs

Promoter

0.00%

How big is Laboratory Corp. of America Holdings?

22-Jun-2025

As of Jun 18, Laboratory Corp. of America Holdings has a market capitalization of $21.72 billion, with net sales of $13.18 billion and a net profit of $731.80 million for the latest four quarters.

As of Jun 18, Laboratory Corp. of America Holdings has a market capitalization of 21,715.97 million, classifying it as a Mid Cap company.<BR><BR>As of Jun 18, the company reported net sales of 13,177.40 million and a net profit of 731.80 million for the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024.<BR><BR>As of December 2024, the company had shareholder's funds amounting to 8,052.20 million and total assets of 18,379.00 million.

Read More

What does Laboratory Corp. of America Holdings do?

22-Jun-2025

Laboratory Corporation of America Holdings is a mid-cap life sciences company in the healthcare diagnostics sector, with recent net sales of $3.345 billion and a net profit of $213 million. Key metrics include a P/E ratio of 28.00, a dividend yield of 1.14%, and a market capitalization of approximately $21.72 billion.

Overview:<BR>Laboratory Corporation of America Holdings is a life sciences company operating in the healthcare diagnostics industry, with a market capitalization in the mid-cap bracket.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3,345 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 213 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 21,715.97 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Dividend Yield: 1.14% <BR>Debt Equity: 0.65 <BR>Return on Equity: 9.28% <BR>Price to Book: 2.61<BR><BR>Contact Details:<BR>Address: 358 S MAIN ST, BURLINGTON NC, 27215-5837 <BR>Tel: 1 336 2291127, 1 336 4365076 <BR>Fax: 1 302 6365454 <BR>Website: https://www.labcorp.com

Read More

Who are in the management team of Laboratory Corp. of America Holdings?

22-Jun-2025

As of March 2022, the management team of Laboratory Corp. of America Holdings includes President and CEO Adam Schechter, with Peter Neupert as the Lead Independent Director and independent directors Kerrii Anderson, Jean-Luc Belingard, Jeffrey Davis, and D. Gary Gilliland.

As of March 2022, the management team of Laboratory Corp. of America Holdings includes Mr. Adam Schechter, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features Mr. Peter Neupert as the Lead Independent Director, along with independent directors Ms. Kerrii Anderson, Mr. Jean-Luc Belingard, Mr. Jeffrey Davis, and Dr. D. Gary Gilliland.

Read More

Is Laboratory Corp. of America Holdings overvalued or undervalued?

20-Sep-2025

As of July 25, 2025, Laboratory Corp. of America Holdings is considered very expensive with a P/E ratio of 28 and an EV to EBITDA of 14.82, despite a strong recent return of 20.86%, as its long-term performance lags behind the S&P 500 and its peers.

As of 25 July 2025, the valuation grade for Laboratory Corp. of America Holdings moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, including a P/E ratio of 28, a Price to Book Value of 2.56, and an EV to EBITDA of 14.82. In comparison, peers such as Quest Diagnostics, Inc. have a P/E of 27.82 and an EV to EBITDA of 17.12, while IQVIA Holdings, Inc. shows a higher P/E of 36.39, suggesting that Laboratory Corp. is relatively less expensive than IQVIA but still on the higher end of the valuation spectrum.<BR><BR>Despite a strong year-to-date return of 20.86% compared to the S&P 500's 12.22%, the long-term performance shows a stark contrast, with a 3-year return of 44.03% versus the S&P's 70.41% and a 5-year return of 75.91% compared to 96.61%. This indicates that while the stock has performed well recently, its valuation may not be justified in light of its peers and the broader market trends.

Read More

Is Laboratory Corp. of America Holdings technically bullish or bearish?

20-Sep-2025

As of July 24, 2025, Laboratory Corp. of America Holdings shows a bullish technical trend supported by positive MACD and KST indicators, despite a mildly bearish Dow Theory signal, and has outperformed the S&P 500 year-to-date with a return of 20.86%.

As of 24 July 2025, the technical trend for Laboratory Corp. of America Holdings has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames. However, the Dow Theory shows a mildly bearish trend on the monthly basis, indicating some caution. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, and the OBV is bullish monthly but only mildly bullish weekly.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 20.86% compared to the S&P 500's 12.22%, and over the past year, it has returned 21.97% versus the S&P 500's 17.14%. Overall, the current technical stance is bullish, with strong indicators supporting this view.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 23,306 Million (Mid Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.06%

stock-summary
Debt Equity

0.60

stock-summary
Return on Equity

9.42%

stock-summary
Price to Book

2.75

Revenue and Profits:
Net Sales:
3,527 Million
(Quarterly Results - Jun 2025)
Net Profit:
238 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.0%
0%
-5.0%
6 Months
2.8%
0%
2.8%
1 Year
10.15%
0%
10.15%
2 Years
17.78%
0%
17.78%
3 Years
8.24%
0%
8.24%
4 Years
4.84%
0%
4.84%
5 Years
53.07%
0%
53.07%

Laboratory Corp. of America Holdings for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Laboratory Corp. of America Holdings technically bullish or bearish?

As of 24 July 2025, the technical trend for Laboratory Corp. of America Holdings has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames. However, the Dow Theory shows a mildly bearish trend on the monthly basis, indicating some caution. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, and the OBV is bullish monthly but only mildly bullish weekly. In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 20.86% compared to the S&P 500's 12.22%, and over the past year, it has returned 21.97% versus the S&P 500's 17.14%. Overall, the current technical stance is bullish, with strong indicators supporting this view....

Read More

Is Laboratory Corp. of America Holdings overvalued or undervalued?

As of 25 July 2025, the valuation grade for Laboratory Corp. of America Holdings moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, including a P/E ratio of 28, a Price to Book Value of 2.56, and an EV to EBITDA of 14.82. In comparison, peers such as Quest Diagnostics, Inc. have a P/E of 27.82 and an EV to EBITDA of 17.12, while IQVIA Holdings, Inc. shows a higher P/E of 36.39, suggesting that Laboratory Corp. is relatively less expensive than IQVIA but still on the higher end of the valuation spectrum. Despite a strong year-to-date return of 20.86% compared to the S&P 500's 12.22%, the long-term performance shows a stark contrast, with a 3-year return of 44.03% versus the S&P's 70.41% and a 5-year return of 75.91% compared to 96.61%. This indicates that while the stock has performed well recently, its ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.28%
EBIT Growth (5y)
-0.76%
EBIT to Interest (avg)
10.71
Debt to EBITDA (avg)
1.97
Net Debt to Equity (avg)
0.65
Sales to Capital Employed (avg)
0.94
Tax Ratio
21.92%
Dividend Payout Ratio
32.58%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
15.08%
ROE (avg)
15.85%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
2.56
EV to EBIT
23.34
EV to EBITDA
14.82
EV to Capital Employed
1.95
EV to Sales
2.02
PEG Ratio
NA
Dividend Yield
1.17%
ROCE (Latest)
8.34%
ROE (Latest)
9.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 153 Schemes (42.25%)

Foreign Institutions

Held by 341 Foreign Institutions (20.08%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 9.51% vs 6.17% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.90% vs 32.47% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,527.30",
          "val2": "3,220.90",
          "chgp": "9.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "568.90",
          "val2": "463.30",
          "chgp": "22.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "57.10",
          "val2": "47.60",
          "chgp": "19.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.10",
          "val2": "-11.60",
          "chgp": "64.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "238.30",
          "val2": "205.60",
          "chgp": "15.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "113.00%",
          "val2": "95.10%",
          "chgp": "1.79%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.97% vs 2.51% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 96.40% vs -62.09% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13,008.90",
          "val2": "12,161.60",
          "chgp": "6.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,037.90",
          "val2": "1,704.60",
          "chgp": "19.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "208.30",
          "val2": "199.60",
          "chgp": "4.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-51.30",
          "val2": "-398.10",
          "chgp": "87.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "747.10",
          "val2": "380.40",
          "chgp": "96.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "87.50%",
          "val2": "92.40%",
          "chgp": "-0.49%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
3,527.30
3,220.90
9.51%
Operating Profit (PBDIT) excl Other Income
568.90
463.30
22.79%
Interest
57.10
47.60
19.96%
Exceptional Items
-4.10
-11.60
64.66%
Consolidate Net Profit
238.30
205.60
15.90%
Operating Profit Margin (Excl OI)
113.00%
95.10%
1.79%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 9.51% vs 6.17% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 15.90% vs 32.47% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
13,008.90
12,161.60
6.97%
Operating Profit (PBDIT) excl Other Income
2,037.90
1,704.60
19.55%
Interest
208.30
199.60
4.36%
Exceptional Items
-51.30
-398.10
87.11%
Consolidate Net Profit
747.10
380.40
96.40%
Operating Profit Margin (Excl OI)
87.50%
92.40%
-0.49%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 6.97% vs 2.51% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 96.40% vs -62.09% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Laboratory Corp. of America Holdings stock-summary
stock-summary
Laboratory Corp. of America Holdings
Miscellaneous
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.
Company Coordinates stock-summary
Company Details
358 S MAIN ST , BURLINGTON NC : 27215-5837
stock-summary
Tel: 1 336 22911271 336 4365076
stock-summary
https://www.labcorp.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."